Who we serve

Journalists

Close up of a microphone
Participants of a press conference

We gladly keep you informed!

It is important to us to inform you as media representatives, journalists and influencers about our activities and to support you in your work as best as possible. 

Hands holding a smartphone

News

Thieme Launches New Open Access Journal Therapeutics NOW

Stuttgart, January 2026 – Thieme is expanding its open access portfolio to promote evidence-based therapeutic development. Therapeutics NOW will publish significant work in fields such as gene therapy, immunotherapy, drug discovery, targeted delivery systems, and personalized medicine. The journal connects experts from academia, industry, and clinical practice worldwide, aiming to rapidly incorporate evidence-based research findings into patient care. Authors benefit from fast, professional and efficient peer review processes to publish and disseminate their research open access. 

Select Crowd Review: A Modern, Collaborative Way to Deliver Fast, High-Quality Peer Review 

September 2025 – Select Crowd Review (SCR) was developed in collaboration with Nobel Laureate Benjamin List, who was Editor-in-Chief at the time. SCR is an innovative system that combines the rigor of traditional peer review with the speed and collaboration of a preselected group of experts who evaluate manuscripts together. Today, SCR is successfully used across six additional Thieme journals in the chemical and medical field.

Our service for you

Portrait Anne Döbler

Anne-Katrin
Döbler,
Senior Vice President Communications

Corporate Communications, Brand Communications 


  • +49 711 8931-115